Paul Choi
Stock Analyst at Goldman Sachs
(3.87)
# 675
Out of 5,091 analysts
114
Total ratings
54.05%
Success rate
9.54%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTCT PTC Therapeutics | Maintains: Sell | $44 → $50 | $76.91 | -34.99% | 8 | Nov 5, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $55 → $100 | $74.24 | +34.70% | 7 | Oct 31, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $45 → $55 | $41.55 | +32.37% | 2 | Oct 29, 2025 | |
| ARVN Arvinas | Downgrades: Sell | $8 → $6 | $13.32 | -54.95% | 4 | Oct 15, 2025 | |
| LNTH Lantheus Holdings | Downgrades: Neutral | $110 → $77 | $62.27 | +23.66% | 2 | Oct 8, 2025 | |
| EWTX Edgewise Therapeutics | Initiates: Neutral | $20 | $23.56 | -15.11% | 1 | Sep 25, 2025 | |
| EXEL Exelixis | Initiates: Buy | $47 | $42.17 | +11.45% | 1 | Sep 17, 2025 | |
| AMRN Amarin Corporation | Maintains: Sell | $7 → $12 | $14.92 | -19.57% | 9 | Jun 25, 2025 | |
| URGN UroGen Pharma | Maintains: Neutral | $16 → $3 | $23.08 | -87.00% | 4 | May 22, 2025 | |
| GOSS Gossamer Bio | Maintains: Buy | $7 → $8 | $3.41 | +134.60% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $5 | $14.90 | -66.44% | 10 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $52 | $44.53 | +16.78% | 2 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $6.58 | +219.15% | 8 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $12 | $13.24 | -9.37% | 3 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $3.91 | -23.27% | 9 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $12 → $10 | $10.97 | -8.84% | 4 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $207.12 | +8.63% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $85 → $60 | $64.13 | -6.44% | 2 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $14.04 | +35.33% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $4.45 | +326.97% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $400 → $50 | $8.36 | +498.09% | 7 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.17 | +2,036.75% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $10.54 | +1,512.90% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $5.40 | +48.15% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $154.99 | -12.90% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $270 → $300 | $57.28 | +423.74% | 2 | Mar 30, 2020 |
PTC Therapeutics
Nov 5, 2025
Maintains: Sell
Price Target: $44 → $50
Current: $76.91
Upside: -34.99%
BridgeBio Pharma
Oct 31, 2025
Maintains: Buy
Price Target: $55 → $100
Current: $74.24
Upside: +34.70%
Kiniksa Pharmaceuticals International,
Oct 29, 2025
Maintains: Buy
Price Target: $45 → $55
Current: $41.55
Upside: +32.37%
Arvinas
Oct 15, 2025
Downgrades: Sell
Price Target: $8 → $6
Current: $13.32
Upside: -54.95%
Lantheus Holdings
Oct 8, 2025
Downgrades: Neutral
Price Target: $110 → $77
Current: $62.27
Upside: +23.66%
Edgewise Therapeutics
Sep 25, 2025
Initiates: Neutral
Price Target: $20
Current: $23.56
Upside: -15.11%
Exelixis
Sep 17, 2025
Initiates: Buy
Price Target: $47
Current: $42.17
Upside: +11.45%
Amarin Corporation
Jun 25, 2025
Maintains: Sell
Price Target: $7 → $12
Current: $14.92
Upside: -19.57%
UroGen Pharma
May 22, 2025
Maintains: Neutral
Price Target: $16 → $3
Current: $23.08
Upside: -87.00%
Gossamer Bio
May 16, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $3.41
Upside: +134.60%
May 2, 2025
Maintains: Neutral
Price Target: $10 → $5
Current: $14.90
Upside: -66.44%
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $44.53
Upside: +16.78%
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $6.58
Upside: +219.15%
Apr 17, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $13.24
Upside: -9.37%
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $3.91
Upside: -23.27%
Apr 17, 2025
Maintains: Sell
Price Target: $12 → $10
Current: $10.97
Upside: -8.84%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $207.12
Upside: +8.63%
Aug 13, 2024
Downgrades: Neutral
Price Target: $85 → $60
Current: $64.13
Upside: -6.44%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $14.04
Upside: +35.33%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $4.45
Upside: +326.97%
Jun 27, 2023
Maintains: Sell
Price Target: $400 → $50
Current: $8.36
Upside: +498.09%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.17
Upside: +2,036.75%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $10.54
Upside: +1,512.90%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $5.40
Upside: +48.15%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $154.99
Upside: -12.90%
Mar 30, 2020
Upgrades: Neutral
Price Target: $270 → $300
Current: $57.28
Upside: +423.74%